BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced its expanded participation with the National Cancer Institute (NCI) and ...
Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker Test, FoundationOne®Liquid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results